A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Recruiting now Phase 2 NCT07652658
Run by AstraZeneca · for 40 and older · All sexes
What this study is about
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Who can join (things the study team will check)
✅ You may be able to join if…
- Age ≥ 40 years
- IPF diagnosis
- Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care
- FVC ≥ 45% predicted of normal
- DLCO corrected for hemoglobin ≥ 25% predicted of normal
🚫 You may not be able to join if…
- ILD other than IPF
- The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan
- Acute exacerbation of IPF
- Lower respiratory tract infection requiring treatment
- Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting
- Heart failure
- History of organ transplantation or is likely to receive lung transplantation
Where this trial is running
- Research Site, Birmingham, Alabama, United States
- Research Site, Phoenix, Arizona, United States
- Research Site, Phoenix, Arizona, United States
- Research Site, Loma Linda, California, United States
- Research Site, Los Angeles, California, United States
- Research Site, Newport Beach, California, United States
- Research Site, Sacramento, California, United States
- Research Site, Stanford, California, United States
- Research Site, Aurora, Colorado, United States
- Research Site, Denver, Colorado, United States
- Research Site, Ocala, Florida, United States
- Research Site, Weston, Florida, United States
+ 178 more sites.
Who to contact
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07652658.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.